The Financial Times: Approval of Biogen Alzheimer’s drug reignites ‘amyloid’ debate

Scientists at UC say restoring a brain protein, not removing amyloid plaques, should be the target

The debate over a new drug to treat Alzheimer's is still going strong, with many experts rebutting the science behind its recent FDA approval. One of the most vocal voices objecting to the new drug is UC's Alberto Espay, MD.   

“The FDA approval will stimulate further investments into a hypothesis that should have long ago been falsified,” Espay told The Finanical Times. 

Espay and a team of researchers at UC and the  Karolinska Institute in Sweden back his position with their recent, and highly publicized study, pointing to a different target for the treatment of Alzheimer's disease. 

Read The Financial Times article, which has been reprinted in several international news outlets, includinh Kenya News.

Read more about Espay and the UC-led study.

Featured image at top of Alberto Espay, MD. Photo/Colleen Kelley/UC Creative + Brand

Impact Lives Here

The University of Cincinnati is leading public urban universities into a new era of innovation and impact. Our faculty, staff and students are saving lives, changing outcomes and bending the future in our city's direction. Next Lives Here.